TABLE 3.

Cumulative Results From Pilot Introduction of DMPA-SC Across 4 Countries, 2014–2016

	Burkina Faso	Niger	Senegal	Uganda
No. of DMPA-SC doses administered	194,965	43,801	120,861	130,673
% of DMPA-SC doses administered to new users	25	42	24a	29
% of DMPA-SC doses administered to adolescent girls and young women
<20 years old	-	16	8a	12
20–24 years old	-	34	26a	32
<25 years old	-	50	34a	44
% of DMPA-SC doses administered to clients switching from:
DMPA-IM	7 (8 public; 2 NGO)	-	13a	16
Other modern methods besides DMPA-IM	17 (18 public; 9 NGO)	-	12a	-
Any modern method	24 (26 public; 11 NGO)	-	25a	-
Proportion of DMPA-SC relative to DMPA-IM where offered in parallel
At the community levelb	-	-	72	75
At all levels	16	-	30	-
% of health facilities reporting a stock-out of DMPA-SC (highest reported)	67	70	<2	9

Abbreviations: DMPA-IM, intramuscular depot medroxyprogesterone acetate; DMPA-SC, subcutaneous depot medroxyprogesterone acetate.

- Data not available.

^aSenegal data derived from the sentinel sites.

^bDMPA-SC available only at the community level in Niger and Uganda.